154 related articles for article (PubMed ID: 10754525)
1. Fragile histidine triad gene expression in primary prostate cancer and in an in vitro model.
Guo Z; Johansson SL; Rhim JS; Vishwanatha JK
Prostate; 2000 May; 43(2):101-10. PubMed ID: 10754525
[TBL] [Abstract][Full Text] [Related]
2. FHIT (fragile histidine triad) gene analysis in cervical intraepithelial neoplasia.
Liu FS; Hsieh YT; Chen JT; Ho ES; Hung MJ; Lin AJ
Gynecol Oncol; 2001 Aug; 82(2):283-90. PubMed ID: 11531281
[TBL] [Abstract][Full Text] [Related]
3. [Sequence analyses of aberrant FHIT transcripts in gastric cancer cell lines].
Lee SH; Kim HS
Korean J Gastroenterol; 2003 Dec; 42(6):476-83. PubMed ID: 14695704
[TBL] [Abstract][Full Text] [Related]
4. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors.
Greenspan DL; Connolly DC; Wu R; Lei RY; Vogelstein JT; Kim YT; Mok JE; Muñoz N; Bosch FX; Shah K; Cho KR
Cancer Res; 1997 Nov; 57(21):4692-8. PubMed ID: 9354423
[TBL] [Abstract][Full Text] [Related]
5. Restored expression of fragile histidine triad protein and tumorigenicity of cervical carcinoma cells.
Wu R; Connolly DC; Dunn RL; Cho KR
J Natl Cancer Inst; 2000 Feb; 92(4):338-44. PubMed ID: 10675384
[TBL] [Abstract][Full Text] [Related]
6. Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies.
Ishii H; Vecchione A; Furukawa Y; Sutheesophon K; Han SY; Druck T; Kuroki T; Trapasso F; Nishimura M; Saito Y; Ozawa K; Croce CM; Huebner K; Furukawa Y
Mol Cancer Res; 2003 Nov; 1(13):940-7. PubMed ID: 14638866
[TBL] [Abstract][Full Text] [Related]
7. Altered expression of the fragile histidine triad gene in primary gastric adenocarcinomas.
Lee SH; Kim WH; Kim HK; Woo KM; Nam HS; Kim HS; Kim JG; Cho MH
Biochem Biophys Res Commun; 2001 Jun; 284(3):850-5. PubMed ID: 11396980
[TBL] [Abstract][Full Text] [Related]
8. Molecular analysis of the FHIT gene in human prostate cancer.
Latil A; Bièche I; Fournier G; Cussenot O; Pesche S; Lidereau R
Oncogene; 1998 Apr; 16(14):1863-8. PubMed ID: 9583683
[TBL] [Abstract][Full Text] [Related]
9. Fragile histidine triad transcription abnormalities and human papillomavirus E6-E7 mRNA expression in the development of cervical carcinoma.
Segawa T; Sasagawa T; Yamazaki H; Sakaike J; Ishikawa H; Inoue M
Cancer; 1999 May; 85(9):2001-10. PubMed ID: 10223242
[TBL] [Abstract][Full Text] [Related]
10. Aberrant FHIT mRNA transcripts are present in malignant and normal haematopoiesis, but absence of FHIT protein is restricted to leukaemia.
Peters UR; Hasse U; Oppliger E; Tschan M; Ong ST; Rassool FV; Borisch B; Tobler A; Fey MF
Oncogene; 1999 Jan; 18(1):79-85. PubMed ID: 9926922
[TBL] [Abstract][Full Text] [Related]
11. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations.
Fong KM; Biesterveld EJ; Virmani A; Wistuba I; Sekido Y; Bader SA; Ahmadian M; Ong ST; Rassool FV; Zimmerman PV; Giaccone G; Gazdar AF; Minna JD
Cancer Res; 1997 Jun; 57(11):2256-67. PubMed ID: 9187130
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of fragile histidine triad expression in prostate carcinoma.
Fouts RL; Sandusky GE; Zhang S; Eckert GJ; Koch MO; Ulbright TM; Eble JN; Cheng L
Cancer; 2003 Mar; 97(6):1447-52. PubMed ID: 12627509
[TBL] [Abstract][Full Text] [Related]
13. Expression of the fragile histidine triad gene in normal rat tissues and human kidney cancer cell lines.
Lee SH; Kim TJ; Kim HY; Kim JG; Park MK; Woo KM; Kim SH; Hwang KY; Nam HS; Min YK; Cho MH
Res Commun Mol Pathol Pharmacol; 2002; 112(1-4):145-57. PubMed ID: 15080505
[TBL] [Abstract][Full Text] [Related]
14. Abnormalities of fragile histidine triad genomic and complementary DNAs in cervical cancer: association with human papillomavirus type.
Muller CY; O'Boyle JD; Fong KM; Wistuba II; Biesterveld E; Ahmadian M; Miller DS; Gazdar AF; Minna JD
J Natl Cancer Inst; 1998 Mar; 90(6):433-9. PubMed ID: 9521167
[TBL] [Abstract][Full Text] [Related]
15. FHIT gene alterations in esophageal cancer and ulcerative colitis (UC).
Zou TT; Lei J; Shi YQ; Yin J; Wang S; Souza RF; Kong D; Shimada Y; Smolinski KN; Greenwald BD; Abraham JM; Harpaz N; Meltzer SJ
Oncogene; 1997 Jul; 15(1):101-5. PubMed ID: 9233782
[TBL] [Abstract][Full Text] [Related]
16. Loss of FHIT expression in transitional cell carcinoma of the urinary bladder.
Baffa R; Gomella LG; Vecchione A; Bassi P; Mimori K; Sedor J; Calviello CM; Gardiman M; Minimo C; Strup SE; McCue PA; Kovatich AJ; Pagano F; Huebner K; Croce CM
Am J Pathol; 2000 Feb; 156(2):419-24. PubMed ID: 10666370
[TBL] [Abstract][Full Text] [Related]
17. Alterations of the FHIT gene in human hepatocellular carcinoma.
Yuan BZ; Keck-Waggoner C; Zimonjic DB; Thorgeirsson SS; Popescu NC
Cancer Res; 2000 Feb; 60(4):1049-53. PubMed ID: 10706123
[TBL] [Abstract][Full Text] [Related]
18. Expression of abnormal transcripts of the FHIT (fragile histidine triad) gene in ovarian carcinoma.
Mandai M; Konishi I; Kuroda H; Nanbu K; Matsushita K; Yura Y; Hamid AA; Mori T
Eur J Cancer; 1998 Apr; 34(5):745-9. PubMed ID: 9713284
[TBL] [Abstract][Full Text] [Related]
19. High frequency of LOH, MSI and abnormal expression of FHIT in gastric cancer.
Huiping C; Kristjansdottir S; Bergthorsson JT; Jonasson JG; Magnusson J; Egilsson V; Ingvarsson S
Eur J Cancer; 2002 Mar; 38(5):728-35. PubMed ID: 11916557
[TBL] [Abstract][Full Text] [Related]
20. Aberrant fragile histidine triad gene transcripts in primary hepatocellular carcinoma and liver cirrhosis.
Gramantieri L; Chieco P; Di Tomaso M; Masi L; Piscaglia F; Brillanti S; Gaiani S; Valgimigli M; Mazziotti A; Bolondi L
Clin Cancer Res; 1999 Nov; 5(11):3468-75. PubMed ID: 10589760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]